Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14017264 | 0.78 | ERBB2 (0.38) | EGFRKDRERBB2AAK1 | |
| SCHEMBL21561513 | 0.78 | ERBB2 (0.41) | EGFRKDRERBB2AAK1 | |
| SCHEMBL20272426 | 0.77 | EGFR (0.48) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL12537638 | 0.74 | EGFR (0.52) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL1219978 | 0.74 | EGFR (0.49) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL16204458 | 0.74 | MAP4K4 (0.47) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL25791621 | 0.71 | EGFR (0.43) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL18879040 | 0.71 | EGFR (0.57) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL14537439 | 0.71 | EGFR (0.43) | EGFRKDRFLT1FLT4IRAK4 | |
| SCHEMBL15682806 | 0.69 | MAP4K4 (0.55) | EGFRKDRIRAK4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2024-07-09 | — | — | US | disclosed |
| EP-3792263-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC (CN) | 2023-03-01 | — | — | EP | disclosed |
| US-20210323979-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-10-21 | — | — | US | disclosed |
| WO-2019214651-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | 南京明德新药研发有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7141571-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-20050288289-A1 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | EGFR 408/4885KDR 821/4885FLT1 899/4885 |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | EGFR 4/4885KDR 222/4885FLT1 114/4885 |
| US-20050288289-A1 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | MAP3K15, MAP4K2, MAP3K20 | EGFR 832/4885KDR 795/4885FLT1 1100/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | EGFR 1009/4885KDR 1746/4885FLT1 1296/4885 |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | EGFR 3/4885KDR 53/4885FLT1 26/4885 |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | EGFR 4/4885KDR 222/4885FLT1 114/4885 |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | ERBB2, ERBB4, ERBB3 | EGFR 4/4885KDR 222/4885FLT1 114/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | EGFR 408/4885KDR 821/4885FLT1 899/4885 |
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 78/4885FLT1 37/4885 |
| US-20210323979-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 78/4885FLT1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.